Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

NCT07573163 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication tirzepatide can help lower blood pressure in adults with mild cortisol overproduction who are scheduled to undergo adrenal gland removal surgery.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 34 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-07 · est. completion 2028-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07573163 ↗

Description as written by the study sponsor.

Mild Autonomous Cortisol Secretion (MACS) is a condition in which an adrenal gland produces excess cortisol and is associated with high blood pressure, diabetes, and weight gain. Surgical removal of the adrenal gland (adrenalectomy) is standard treatment, but some patients continue to have metabolic health problems after surgery. This randomized study will evaluate whether treatment with tirzepatide after adrenalectomy improves metabolic outcomes in patients with MACS compared with adrenalectomy alone.

Treatments tested

Tirzepatide Drug

Tirzepatide will be initiated at the lowest dose of 2.5 mg once weekly for 4 weeks. The dose will then be titrated every 4 weeks based on patient tolerance to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
Standard medical treatment Other

Participants will receive postoperative care and follow up per institutional standard-of-care practices

Main thing measured	Change in systolic blood pressure
Sponsor	Alaa Sada
Conditions studied	Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07573163 ↗